Is Sanofi (SNY) Approaching a Breakthrough in Rare Neurological Disease Treatment?
TheFly reported on May 27 that the US Food and Drug Administration (FDA) has granted priority review to SNY’s New Drug Application for venglustat, an investigational oral glucosylceramide synthase inhibitor...






